MedTrace Logo

Lithium As a Treatment to Prevent Impairment of Cognition in Elders

NCT03185208 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2025-09-11

Study results available
· View outcomes & findings →

Summary

Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.

Conditions

Interventions

DRUG

Lithium Carbonate

See lithium carbonate arm

DRUG

Placebo oral capsule

See placebo arm

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Ariel Gildengers, MD

    lead OTHER

Principal Investigators

  • Ariel Gildengers, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2024-08-06
Completion
2024-08-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185208 on ClinicalTrials.gov